October 4, 2017
Results from this study demonstrated patients with early gout treated with febuxostat had improvements in MRI synovitis and a decrease in gout flares compared with patients in a placebo group.
“Typically, studies of urate-lowering therapy recruit people with longstanding gout,” Nicola Dalbeth, MD, FRACP, study co-author, rheumatologist and professor at the department of medicine at the University of Auckland in New Zealand, told Healio Rheumatology. “This placebo-controlled [randomized controlled trial] RCT examined the effect of urate-lowering therapy in people with earlier disease who had experienced only one or two gout flares. The key finding of this study was that in this patient group, the urate-lowering drug febuxostat reduced joint inflammation detected by MRI scanning and also reduced the frequency of gout flares over the 2-year study period.”